Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06869551 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 47 to 48 Eligibility criteria expanded, about 7 words · Secondary endpoints: details revised at 2 of 17 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 2 of 17 entries
  2. Study sites revised (47)v15 See this version in full on ClinicalTrials.gov ↗
  3. Study sites revised (47)v14 See this version in full on ClinicalTrials.gov ↗
  4. Secondary endpoints revised (17) Study sites revised (47)v13 Show 1 more changeShow less
    • Study sites revised (47)

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites revised (47)v12 See this version in full on ClinicalTrials.gov ↗
Show 10 earlier versionsHide 10 earlier versions
  1. Study sites: 46 to 47v11
  2. Study sites: 47 to 46v10
  3. Study sites: 42 to 47v9
  4. Study sites revised (42)v8 See this version in full on ClinicalTrials.gov ↗
  5. Re-verified, no change to tracked fieldsv7
  6. Study sites: 41 to 42v6
  7. Study sites: 37 to 41v5
  8. Study sites revised (37)v4 See this version in full on ClinicalTrials.gov ↗
  9. Study sites: 35 to 37v3
  10. Study sites: 32 to 35 Start date changed from estimate of Mar 10, 2025 to Mar 13, 2025v2 Show 1 more changeShow less
    • Start date changed from estimate of Mar 10, 2025 to Mar 13, 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Trial Details
NCT Number NCT06869551
Lead Sponsor Bristol-Myers Squibb
Conditions Juvenile Psoriatic Arthritis
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov